Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ConfometRx

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

UCB joins clinical trial data sharing portal

Follows GSK, Lilly, Roche and others in committing to transparency website

- PMLiVE

UCB taps EU for €75m in R&D funding

Agrees innovative risk-sharing finance deal with European Investment Bank

- PMLiVE

Epilepsy takes centre stage in UK

National Epilepsy Week aims to raise awareness of the neurological condition

- PMLiVE

UCB names Jean-Christophe Tellier as Doliveux’s successor

He will take over take over leadership at the Belgium pharma company next year

- PMLiVE

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

- PMLiVE

Matthew Speers appointed as new chief executive of PAGB

UCB's former UK and Ireland general manager will take up post next year

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


- PMLiVE

UCB wins extra Cimzia approval in US

FDA backs drug for use in patients with active psoriatic arthritis 

- PMLiVE

VIDEO interview: Neil Weir, UCB

Senior vice president of global research at UCB discusses the importance of patient-centricity and the value of collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links